The FDA has approved Novartis’ Diovan HCT (valsartan/hydrochlorothiazide tablets) and Exforge (amlodipine/valsartan tablets) as first-line therapies for hypertension in patients likely to need ...

Discover comprehensive details about Amlodipine, Valsartan and Hydrochlorothiazide, including its pronunciation, uses, dosage instructions, indications, and guidelines on how and when to take it ...

The FDA approval of Diovan HCT and Exforge for first-line use reinforces current US guideline recommendations to start appropriate patients on combination therapy. Research suggests that up to 80% ...

The FDA has approved Novartis‘ Exforge HCT (amlodipine/valsartan/hydrochlorothiazide) tablets, a combination product containing a calcium channel blocker, an ...

Exforge HCT®, which is marketed by Novartis, combines the CCB amlodipine, the ARB valsartan, and the diuretic hydrochlorothiazide (HCTZ). [11] Exforge HCT® is indicated for the treatment of ...

Exforge HCT ® (Amlodipine, Valsartan, Hydrochlorothiazide) Tablets, marketed by Novartis Pharmaceuticals, had annual sales of approximately $158 million in the United States, according to ...

Exforge is a combination of two blood pressure blockbusters: Diovan from Novartis (down $0.38 to $55.14, Charts), which totaled $4.2 billion in 2006 sales, and Pfizer's Norvasc.

The US Food and Drug Administration has approved the two single-pill combos – Diovan HCT/Co-Diovan (valsartan and hydrochlorothiazide) and Exforge (amlodipine and valsartan) – as initial therapies in ...

Teva Pharmaceutical Industries Limited ( TEVA) has launched its generic version of Novartis' ( NVS) Exforge HCT (amlodipine, valsartan, hydrochlorothiazide) tablets in the U.S. Exforge HCT is ...